2.10
前日終値:
$2.11
開ける:
$2.13
24時間の取引高:
8.49M
Relative Volume:
6.73
時価総額:
$282.58M
収益:
-
当期純損益:
$-101.70M
株価収益率:
-1.1075
EPS:
-1.8961
ネットキャッシュフロー:
$-84.35M
1週間 パフォーマンス:
+8.25%
1か月 パフォーマンス:
-11.02%
6か月 パフォーマンス:
+2.44%
1年 パフォーマンス:
+197.96%
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
名前
Alx Oncology Holdings Inc
セクター
電話
650-466-7125
住所
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ALXO
Alx Oncology Holdings Inc
|
2.10 | 271.82M | 0 | -101.70M | -84.35M | -1.8961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 開始されました | Wells Fargo | Overweight |
| 2026-03-06 | 再開されました | UBS | Buy |
| 2025-11-13 | 開始されました | Jefferies | Buy |
| 2025-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-06 | 開始されました | UBS | Buy |
| 2021-02-10 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 開始されました | Credit Suisse | Outperform |
| 2020-08-11 | 開始されました | Jefferies | Buy |
| 2020-08-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Alx Oncology Holdings Inc (ALXO) 最新ニュース
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO) - Stock Titan
ALX Oncology Holdings Inc (ALXO) Cash Flow - TradingKey
2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC - MarketBeat
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010 - TradingKey
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.020|Chg%:-0.010 - TradingKey
TradingKey - TradingKey
ALX Oncology Holdings Inc. Revenue Breakdown – NASDAQ:ALXO - TradingView
ALX Oncology Holdings Inc (ALXO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alx Oncology Holdings, Inc. (ALXO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Alx Oncology Holdings, Inc. (ALXO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Alx Oncology Holdings, Inc. (ALXO) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
ALX Oncology (ALXO) Status Update Summary - Quartr
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
ALXO Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ALX Oncology (ALXO) Jefferies London Healthcare Conference 2025 Summary - Quartr
ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations - Stock Titan
ALXOAlx Oncology Holdings Inc Options - Finviz
ALX Oncology (ALXO) Edges Higher as Biotech Sector Shows Selective InterestLast Point Support - DonanımHaber
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
ALX Oncology Appoints New Chairman Amid Leadership Changes - TipRanks
ALX Oncology grants 500,000-share option to new general counsel - Stock Titan
ALX Oncology's Corey Goodman resigns as Chairman and director - TradingView
Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair - Stock Titan
ALX Oncology names Scott Garland chairman, adds general counsel - Investing.com UK
ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com - Investing.com India
ALXO Welcomes New Leadership with Board Changes - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - Investing News Network
ALX Oncology appoints Scott Garland as chairman and Michael Listgarten as general counsel to strengthen leadership - Traders Union
ALX Oncology replaces its chairman and adds a new general counsel - Stock Titan
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2500 Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Index - marketscreener.com
ALX Oncology Holdings Inc. (ALXO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell Microcap Index - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Index - marketscreener.com
ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline - timothysykes.com
ALXO Rises As ALX Oncology Showcases Pipeline At Jefferies - StocksToTrade
Price to sales forward of ALX Oncology Holdings Inc. – NASDAQ:ALXO - TradingView
Price to book forward of ALX Oncology Holdings Inc. – NASDAQ:ALXO - TradingView
ALX Oncology Secures New $50 Million Loan Facility - The Globe and Mail
Alx Oncology HoldingsEnters Loan And Security Agreement With HSBC Ventures On June 25, 2026SEC Filing - TradingView
ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility - Stock Titan
Alx Oncology Holdings Inc (ALXO) 財務データ
収益
当期純利益
現金流量
EPS
Alx Oncology Holdings Inc (ALXO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Mar 19 '26 |
Sale |
2.17 |
12,311 |
26,715 |
293,609 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Mar 19 '26 |
Sale |
2.17 |
903 |
1,960 |
86,805 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 18 '26 |
Sale |
2.27 |
565 |
1,283 |
87,708 |
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
大文字化:
|
ボリューム (24 時間):